Multi-Country Herpes Immunotherapy Clinical Study Continues
WEBMar 5, 2024 · A leading global vaccine developer has announced that their investigational vaccine candidate for Herpes Simplex Virus (HSV) is undergoing a phase 1/2 clinical trial for the first time in Europe, England, and the United States. GlaxoSmithKline plc. (GSK), known for its extensive range of vaccines for various conditions, including RSV, meningitis, and shingles, is conducting an innovative study ...
HSV Treatment Readies for Approval — Precision Vaccinations News
WEBA recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV). As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of herpes, HSV-1 and HSV-2.
34 Countries Identified in the Latest Polio Outbreak Alert
WEBJun 22, 2024 · The Global Polio Eradication Initiative (GPEI) released its weekly update, which indicated that three countries reported new polio cases as the poliovirus continues to spread in 2024. On June 19, 2024, the GPEI reported that Afghanistan confirmed one wild poliovirus type 1 (WPV1), bringing the total number of cases in 2024 to six. Nigeria reported three cases of circulating vaccine-derived ...
U.S. Government Takes Herpes Vaccine Development Lead
WEBApr 4, 2024 · To address this shortcoming, the U.S. government issued a Notice of Special Interest (NOSI) NOT-AI-24-028 on March 27, 2024, intending to stimulate additional focus on developing diagnostics, therapeutics, and vaccines targeting HSV. This NOSI, issued by the U.S. National Institute of Allergy and Infectious Diseases, focuses on furthering the ...
Only 24% of Older People Protected From RSV
WEB4 days ago · The American Lung Association (ALA) today announced it is launching an educational campaign to help raise awareness about respiratory syncytial virus (RSV) and steps to help prevent RSV infection. RSV is a highly contagious virus that spreads through close contact with infected individuals. This campaign is essential since only 24% of older adults have received one of the three approved RSV ...
Herpes Vaccine Candidate Advances in 2023 - Precision …
WEBJan 8, 2023 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on ...
mRNA-Based Flu Shot Focuses on Improving Performance in …
WEBApril 4, 2024 • 9:47 am CDT. As influenza vaccine producers prepare for the 2024 - 2025 flu season, innovative vaccine candidates are progressing in clinical research, focused on enhancing efficacy and safety. CureVac N.V. today announced interim data from an ongoing Phase 2 study, which is part of the combined Phase 1/2 study of its seasonal ...
Three Novel Immune-based Therapies for HIV Cure Launch Clinical …
WEBApril 22, 2024 • 7:33 am CDT. ACTG is the largest HIV clinical trials network. (Precision Vaccinations News) Although antiretroviral treatment (ART) can help manage the impact of the Human Immunodeficiency Virus (HIV), it is not a cure. People living with HIV need to take the treatment for their entire lives to suppress viral replication and ...
Chronic Hepatitis B Treatment Receives U.S. FDA Fast Track …
WEBFeb 13, 2024 · GSK plc announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). GSK said on February 12, 2024, Bepirovirsen is the only single agent in phase III development that has shown the potential to achieve clinically meaningful functional cure ...
Trivalent Influenza Vaccines Will Be Delivered for the 2024-2025 …
WEBMar 6, 2024 · CSL Seqirus today announced that it is fully equipped to deliver its influenza vaccine portfolio for the 2024-2025 U.S. season. The new vaccine will be based on the trivalent strains recommended by the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC), which confirmed the viral strain selection in a March 5, 2024 meeting.
- Some results have been removed